CAN10 is designed to inhibit the pro-inflammatory cytokines through its action on the interleukin-1 receptor accessory ...

First patient dosed in Adcentrx's ADRX-0706 Phase 1b , advancing a new potential treatment option for cancer patients.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...

On December 2, 2024, Apogee Therapeutics, a clinical-stage biotechnology company, released a press release detailing the significant advancements made in its novel biologic programs for Inflammatory ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Senti Bio (SNTI)science reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential ...

MBX Biosciences (MBX) announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the ...

Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Dr ...

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared ...

Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food ...

R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...

South Korean biopharmaceutical firm Celltrion said Monday it has submitted an investigational new drug application to the US ...